publication venue for
- Calibration Procedures for Multi-Center Dosimetry Studies with Lu-177 Radiopharmaceuticals: Early Experience from the Canadian Cancer Trial Group PR.21 Trial (NCT 04663997) 2022
- Use of Iterative Reconstruction for Dose Optimisation of Paediatric Tc-99m MDP Bone SPECT 2019
- Comparison study of TCO-functionalized vector systems for in vivo click chemistry using [In-111]In-DOTA-Tetrazine 2017
- Evaluation of the physicochemical properties of (99m)Technetium-Exametazime (Medi-Exametazime (TM)) and its biodistribution in a pre-clinical mouse model 2017
- Stability assessment after reconstitution and investigation of the biodistribution in a pre-clinical mouse model of 99mTechnetium-Sestamibi (Cardiovis (TM)) 2017
- Value of Myocardial perfusion Scintigraphy in Predicting cardiac Risk in Abdominal Aortic Aneurysm (AAA) Repair 2014
- The feasibility, acceptability and safety of Molecular Breast Imaging (MBI) using a breast specific gamma camera and 99mTc-sestamibi in patients with a high risk of breast cancer 2013
- Beyond Dose Guidelines: Lower Minimum Radiopharmaceutical Administered Doses in Pediatric Hepatobiliary Scintigraphy: Application of Enhanced Planar Processing. 2012
- Somatostatin-based Radiopeptide Therapy with [Lu-177-DOTA]-TOC versus [Y-90-DOTA]-TOC in Neuroendocrine Tumors 2012
- Somatostatin-based Radiotherapy with [Y-90-DOTA]-TOC in Neuroendocrine Tumors: Long-Term Outcome of a Phase I Dose Escalation Study 2012
- Response, Survival and Long-Term Toxicity of [90Yttrium-DOTA]-TOC in Metastasized Neuroendocrine Cancers 2011
- [90Yttrium-DOTA]-TOC vs. [90Yttrium-DOTA]-TOC plus [177Lutetium-DOTA]-TOC in Metastasized Neuroendocrine Cancers 2011
- The role of dynamic renal scintigraphy and indirect radionuclide cystography with mercaptoacetyltriglycine in detection of vesicoureteral reflux and evaluation of renal parenchymal lesions 2010
- CLINICAL USE OF TC-99M HMPAO FOLLOWING ACUTE AND NON-ACUTE CEREBRAL TRAUMA 1988
- Updated practice guideline for dual-energy X-ray absorptiometry (DXA).. 1-25. 2024
- Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma—a proof of concept study. 51:1409-1420. 2024
- [18F]FNDP PET neuroimaging test–retest repeatability and whole-body dosimetry in humans. 50:3659-3665. 2023
- First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2. 50:2386-2393. 2023
- Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma. 49:4382-4393. 2022
- Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box. 49:18-29. 2021
- First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET. 48:3122-3128. 2021
- Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. 46:1102-1110. 2019
- Reply to ‘Single high dose versus repeated bone-targeted radionuclide therapy’. 45:515-517. 2018
- Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. 44:1671-1678. 2017
- Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival. 44:620-629. 2017
- The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. 44:468-475. 2017
- Short-term changes in arterial inflammation predict long-term changes in atherosclerosis progression. 44:141-150. 2017
- Nuclear cardiology practice and associated radiation doses in Europe: results of the IAEA Nuclear Cardiology Protocols Study (INCAPS) for the 27 European countries. 43:718-728. 2016
- Towards tailored radiopeptide therapy. 42:1231-1237. 2015
- Beyond current guidelines: reduction in minimum administered radiopharmaceutical activity with preserved diagnostic image quality in pediatric hepatobiliary scintigraphy. 41:2346-2353. 2014
- The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. 41:1976-1988. 2014
- Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. 41:214-222. 2014
- Patient-specific dosimetry for intracavitary 32P-chromic phosphate colloid therapy of cystic brain tumours. 40:1532-1541. 2013
- The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. 39:344-353. 2012
- Seasonal variation in the effect of constant ambient temperature of 24°C in reducing FDG uptake by brown adipose tissue in children. 37:1854-1860. 2010
- Constant ambient temperature of 24°C significantly reduces FDG uptake by brown adipose tissue in children scanned during the winter. 36:602-606. 2009
- Bilateral adrenal metastases from malignant melanoma: concordant findings on 18F-FDG and 18F-FDOPA PET. 33:854-855. 2006
- The acute effect of methylphenidate on cerebral blood flow in boys with attention-deficit/hyperactivity disorder. 30:423-426. 2003
- Limbic system perfusion in Alzheimer's disease measured by MRI-coregistered HMPAO SPET. 29:899-906. 2002
- Uses and limitations of renal scintigraphy in renal transplantation monitoring. 27:871-879. 2000
- The time course of metabolites in human plasma after 6-[ 18 F]fluoro- l - m -tyrosine administration. 26:1407-1412. 1999
- Clinical experience with intra lymphatic administration of111In-labelled monoclonal antibody PAY 276 for the detection of pelvic nodal metastases in prostatic carcinoma. 16:149-156. 1990
- Breast cancer imaging with mouse monoclonal antibodies. 15:655-660. 1989
- Initial experience with Tc-99m-HM-PAO in the study of brain tumors. 14:39-44. 1988
- Evaluation of lung epithelial permeability. 13:S58-S62. 1987
- Methodologic considerations in mucociliary clearance and lung epithelial absorption measurements. 13:S45-S52. 1987